In short
Clinical trials are investigating RO7795081 in people with type 2 diabetes. These studies are looking at whether RO7795081 can improve blood sugar control and how it compares with placebo and semaglutide. The main focus is on efficacy and safety in adults with type 2 diabetes.
Key points
- Clinical trials are studying RO7795081 in people with type 2 diabetes. The available trial is a Phase 2, interventional study with 236 planned participants. It compares RO7795081 with placebo and semaglutide, including several oral semaglutide dose groups. The main goal is to see the change in HbA1c from baseline to Week 30. The study is authorised and focuses on blood sugar control in adults with type 2 diabetes.
Trial overview
The available study of RO7795081 is an interventional study, which means researchers give study treatments and compare results between groups. It is designed for people with type 2 diabetes mellitus (T2D) and is currently Authorised.
Who can participate
The trial is focused on people with type 2 diabetes. The study data do not give more details about age, sex, or other entry rules, so only the condition-based target group can be confirmed from the source.
Treatments being compared
The study compares RO7795081 with placebo and with semaglutide. A placebo is an inactive treatment used to help show whether the study medicine has an effect. The trial record also lists several oral semaglutide dose groups, including Rybelsus 3 mg, 4 mg, 7 mg, 9 mg, and 14 mg tablets, plus an oral GLP-1R agonist capsule listed as CT-996 in the intervention section.
Study phase and design
This is a Phase 2 trial. Phase 2 studies are usually early studies that look more closely at whether a treatment may work and continue to monitor safety. The planned enrollment is 236 people, which means the study aims to include 236 participants.
What the study measures
The main endpoint is the change in HbA1c from baseline at Week 30. HbA1c is a blood test that shows average blood sugar over time, so this endpoint helps researchers see whether RO7795081 improves blood sugar control. The brief summary says the study is evaluating the effect of RO7795081 compared with placebo on HbA1c.